Holen Sie sich die Stockscreener-App
0.3977
1.84%
0.0072
Handel nachbörslich:
.40
0.0023
+0.58%
Schlusskurs vom Vortag:
$0.3905
Offen:
$0.3922
24-Stunden-Volumen:
353.13K
Relative Volume:
0.66
Marktkapitalisierung:
$28.35M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-123.46M
KGV:
-0.1536
EPS:
-2.59
Netto-Cashflow:
$-104.11M
1W Leistung:
-2.07%
1M Leistung:
-22.02%
6M Leistung:
-35.23%
1J Leistung:
-69.87%
1-Tages-Spanne:
$0.3899
$0.4093
1-Wochen-Bereich:
$0.36
$0.4299
52-Wochen-Spanne:
$0.2601
$2.525
Bioatla Inc Stock (BCAB) Company Profile
Firmenname
Bioatla Inc
Sektor
Branche
Telefon
858-558-0708
Adresse
11085 TORREYANA ROAD, SAN DIEGO
Vergleichen Sie BCAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.3977 | 28.35M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-09-15 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-05-05 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-03-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-06-28 | Eingeleitet | ROTH Capital | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-01-11 | Eingeleitet | BTIG Research | Buy |
| 2021-01-11 | Eingeleitet | Credit Suisse | Outperform |
| 2021-01-11 | Eingeleitet | JP Morgan | Overweight |
| 2021-01-11 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Bioatla Inc Aktie (BCAB) Neueste Nachrichten
BioAtla, Inc. (NASDAQ:BCAB) Shares Purchased by Two Sigma Investments LP - Defense World
Jane Street Group LLC Purchases 100,204 Shares of BioAtla, Inc. (NASDAQ:BCAB) - Defense World
BioAtla, Inc. (NASDAQ:BCAB) Stock Position Lowered by Two Sigma Advisers LP - Defense World
Millennium Management LLC Cuts Stock Position in BioAtla, Inc. (NASDAQ:BCAB) - Defense World
BioAtla (NASDAQ:BCAB) Upgraded by Wall Street Zen to Hold Rating - Defense World
BioAtla presents Phase 2 Oz-V clinical trial data at ASCO 2025 - MSN
Why Did BioAtla Inc (NASDAQ: BCAB) Drop So Much? - Stocksregister
BioAtla reports promising trial results for cancer drug By Investing.com - Investing.com South Africa
BioAtla reports promising trial results for cancer drug - Investing.com
BioAtla (BCAB) Showcases Promising Data for Ozuriftamab Vedotin in Key Cancer Trial | BCAB Stock News - GuruFocus
BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen - The Manila Times
BioAtla's New Cancer Drug Achieves 13x Better Response Rate Than Standard Treatment in Phase 2 Trial - Stock Titan
BioAtla’s SWOT analysis: CAB platform stock faces pivotal year amid clinical trials - Investing.com Nigeria
Dimensional Fund Advisors LP Sells 86,264 Shares of BioAtla, Inc. (NASDAQ:BCAB) - Defense World
BioAtla receives Nasdaq delisting warning By Investing.com - Investing.com India
BioAtla receives Nasdaq delisting warning - Investing.com Australia
BioAtla Receives Nasdaq Non-Compliance Notice - TipRanks
HC Wainwright Issues Negative Estimate for BioAtla Earnings - Defense World
HC Wainwright Predicts BioAtla’s Q1 Earnings (NASDAQ:BCAB) - Defense World
BioAtla Inc (NASDAQ: BCAB): Is Its Value Too High Compared To Others? - Stocksregister
Analysts Offer Insights on Healthcare Companies: BioAtla (BCAB), Relay Therapeutics (RLAY) and Crispr Therapeutics AG (CRSP) - The Globe and Mail
BioAtla stock holds $1 target, JMP affirms Market Outperform By Investing.com - Investing.com Nigeria
BioAtla at Citizens JMP Life Sciences: Strategic Partnerships in Focus By Investing.com - Investing.com India
BioAtla at Citizens JMP Life Sciences: Strategic Partnerships in Focus - Investing.com Australia
Bioatla Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Gaining Ground: BioAtla Inc (BCAB) Closes Lower at 0.48, Down -8.19 - DWinneX
BioAtla, Inc. (NASDAQ:BCAB) Q1 2025 Earnings Call Transcript - Insider Monkey
BioAtla Q1 2025 Earnings Call Transcript - MarketBeat
BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress - The Manila Times
BioAtla Inc (BCAB) Q1 2025 Earnings Call Highlights: Promising Clinical Progress Amid Financial ... By GuruFocus - Investing.com Canada
BioAtla (NASDAQ:BCAB) vs. Novavax (NASDAQ:NVAX) Head-To-Head Comparison - Defense World
Bioatla, Inc. Earnings Call Highlights Clinical Success - TipRanks
BioAtla, Inc. Reports Q1 2025 Financial Results - TipRanks
Earnings call transcript: Bioatla beats Q1 2025 earnings expectations - Investing.com
BioAtla, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:BCAB) - Seeking Alpha
BioAtla (BCAB) Advances Cancer Treatment with Promising Study Re - GuruFocus
Earnings call transcript: Bioatla beats Q1 2025 earnings expectations By Investing.com - Investing.com UK
BioAtla (BCAB) Advances Cancer Treatment with Promising Study Results | BCAB Stock News - GuruFocus
BioAtla reports Q1 EPS (26c), consensus (29c) - TipRanks
BioAtla Reports Breakthrough: Cancer Drug Triples Survival Rate vs Standard Treatment in Lung Cancer Study - Stock Titan
BioAtla, Inc. (NASDAQ:BCAB) Shares Acquired by Renaissance Technologies LLC - Defense World
There is no doubt that BioAtla Inc (BCAB) ticks all the boxes. - Sete News
BioAtla Inc (BCAB) shows promising results - uspostnews.com
BioAtla Reveals Next-Gen Cancer Treatment Progress: Key Updates Coming at Citizens Conference - Stock Titan
BCAB: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
An Analysis of BioAtla Inc (BCAB)’s Potential Price Growth - knoxdaily.com
BioAtla Q1 2025 Earnings: Biotech Leader to Share Latest Cancer Treatment Progress on May 6 - Stock Titan
BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025 - Yahoo Finance
Bank of Montreal Can Sells 522,252 Shares of BioAtla, Inc. (NASDAQ:BCAB) - Defense World
Finanzdaten der Bioatla Inc-Aktie (BCAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):